<code id='F15FEFDDAC'></code><style id='F15FEFDDAC'></style>
    • <acronym id='F15FEFDDAC'></acronym>
      <center id='F15FEFDDAC'><center id='F15FEFDDAC'><tfoot id='F15FEFDDAC'></tfoot></center><abbr id='F15FEFDDAC'><dir id='F15FEFDDAC'><tfoot id='F15FEFDDAC'></tfoot><noframes id='F15FEFDDAC'>

    • <optgroup id='F15FEFDDAC'><strike id='F15FEFDDAC'><sup id='F15FEFDDAC'></sup></strike><code id='F15FEFDDAC'></code></optgroup>
        1. <b id='F15FEFDDAC'><label id='F15FEFDDAC'><select id='F15FEFDDAC'><dt id='F15FEFDDAC'><span id='F15FEFDDAC'></span></dt></select></label></b><u id='F15FEFDDAC'></u>
          <i id='F15FEFDDAC'><strike id='F15FEFDDAC'><tt id='F15FEFDDAC'><pre id='F15FEFDDAC'></pre></tt></strike></i>

          Wikipedia

          Wikipedia

          author:focus    Page View:8
          Tome cofounders Jonathan Gootenberg, left, and Omar Abudayyeh, a scientific team that's trying to reinvent gene editing for a new era of biotech innovation.
          Suzanne Kreiter/Globe staff

          WATERTOWN — Their brainstorming began in an MIT class in 2010 when the eager undergrads shot each other emails about how to solve a bioengineering equation. It has continued for 14 years over sushi dinners, between Marvel movies, and during rowing-machine workouts.

          Together, Omar Abudayyeh, 33, and Jonathan Gootenberg, 32, have probed the mysteries of genomic editing and COVID detection. They co-published 10 scientific papers, helped launch two medical-diagnostic companies, and cofounded a Watertown startup, Tome Biosciences, that reengineers genes and cells to cure diseases. They also run the Abudayyeh-Gootenberg Lab at Harvard.

          advertisement

          Gootenberg and Abudayyeh are an unusual pair, two scientists — a Jewish American and a Palestinian American — who prefer working together in a field that often draws solitary researchers and rewards individual achievement.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          explore

          Psychedelics group wrestles with new pharma identity
          Psychedelics group wrestles with new pharma identity

          OliviaGoldhill/STATDENVER—Hecouldhavebeenarockstar,areligiousicon,thewayecstaticapplausefromthousand

          read more
          What drug price negotiations mean for Medicare Part D
          What drug price negotiations mean for Medicare Part D

          AdobeAftertherecentannouncementofthefirst10drugsselectedforMedicarepricenegotiation,muchhasbeendiscu

          read more
          Heart attack and stroke risk calculators need revising
          Heart attack and stroke risk calculators need revising

          AdobeForbusyprimarycarephysicianslikeme,anannualphysicalwitha27-year-oldmaleisablessing.Sincewe’real

          read more

          'Make People Better': The CRISPR babies story you probably don't know

          Thebirthofgeneticallyengineeredtwingirls,nicknamedLuluandNana,atanundisclosedhospitalinChina,wasanno